Disease reactivation after switching from natalizumab to daclizumab


Discontinuation of natalizumab can lead to severe rebound of disease activity in patients with relapsing–remitting multiple sclerosis (RRMS); nevertheless, the treatment regimen in this clinical situation remains controversial. We report the case of a 25-year-old male patient with RRMS who was clinically stable under 3 years of natalizumab before treatment… (More)
DOI: 10.1007/s00415-017-8622-9

1 Figure or Table


  • Presentations referencing similar topics